<DOC>
	<DOC>NCT00329095</DOC>
	<brief_summary>This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.</brief_summary>
	<brief_title>An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance</brief_title>
	<detailed_description>This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Currently using one or two topical ocular hypotensive medications Hypersensitivity to any component of medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Compliance</keyword>
</DOC>